Stay updated with breaking news from Jordyn tarazi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene, Ltd.: BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021 Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2021 financial results after the market closes on Monday, May 17, 2021. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business. ....
CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement into IND-enabling activities. CB5138-3 is a CB5138 Analog, a novel class of molecules derived from a natural, mitochondrially encoded peptide source discovered by CohBar, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. IPF is a chronic, progressive, debilitating and usually fatal interstitial lung disease that affects approximately 100,000 people in the U.S. This orphan disease results in fibrotic scarring of the lungs. ....